4
Changes in Ownership
Xilio Therapeutics, Inc. Filed Acc 0001415889-25-000407
Chief Financial Officer sold 6,954 shares at $0.98 ($6,841)
- Chief Financial Officer acquired 19,375 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Frankenfield Christopher James Chief Financial Officer | 2025-01-01 | Option exercise 10b5-1 | +19,375 | 19,375 | D | ||
| Frankenfield Christopher James Chief Financial Officer | 2025-01-02 | Sale 10b5-1 | −6,954 | $0.98 | $6,841 | 12,421 | D |
| Derivatives | |||||||
| Frankenfield Christopher James Chief Financial Officer | 2025-01-01 | Option exercise · Restricted Stock Units 10b5-1 | −19,375 | 58,125 | D | ||
| Frankenfield Christopher James Chief Financial Officer | 2025-01-01 | Grant or award · Stock Option (right to buy) 10b5-1 | +251,000 | 251,000 | D | ||
| Open-market sales · 6,954 sh · avg $0.98 · $6,841 | |||||||
Loading xslF345X05/form4-01032025_040116.xml…